Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …

Aberrancy in cell cycle progression is one of the fundamental mechanisms underlying
tumorigenesis, making regulators of the cell cycle machinery rational anticancer therapeutic …

Many diseases are driven by proteins that are aberrantly ubiquitinated and degraded. These
diseases would be therapeutically benefited by targeted protein stabilization (TPS). Here we …

Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic
paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target …

DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA
mutations, which also provides cancer-specific vulnerabilities that can be targeted by …

Indoleamine 2, 3-dioxygenase 1 (IDO1) is a potent immunosuppressive enzyme that inhibits
the antitumor immune response through both tryptophan metabolism and non-enzymatic …

Simple Summary Defective DNA damage response (DDR) is a hallmark of cancer leading to
genomic instability. Up to 15–20% of colorectal cancers carry alterations in DDR. However …

Mitosis is the process of cell division and is regulated by checkpoints in the cell cycle. G1-S,
S, and G2-M are the three main checkpoints that prevent initiation of the next phase of the …

Abstract The Ser/Thr protein kinase Wee1 plays a regulatory role at the G 2/M checkpoint by
phosphorylating CDK1 when DNA is damaged to allow time for DNA to repair, disruption of …